In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 27, 2020
AAPS Announces New Executive Director
Author(s)BioPharm International Editors
Tina Morris will be taking on the role of executive director for AAPS.
Advertisement
The American Association of Pharmaceutical Scientists (AAPS) announced on Jan. 23 that it has appointed Tina Morris, PhD, as its new executive director.
Morris is currently vice-president of Scientific and Regulatory Affairs at the Parenteral Drug Association, and, prior to her new position, she worked for Human Genome Sciences, Ciphergen Biosystems, and the US Pharmacopeia, according to a company press release.
“The Board of Directors is very excited to welcome Dr. Morris to AAPS,” said Dr. Joseph Polli, AAPS president, in the press release. “Dr. Morris will bring a strong scientific and regulatory vision, as well as extensive association leadership to this role. Tina has made significant scientific contributions at every stage of her professional career. AAPS is eager to have her apply her skills to advancing the capacity of our members and the pharmaceutical sciences.”
“I am honored and excited to be joining an organization that has meant so much to my own development in the field of pharmaceutical sciences over the years,” Morris added in the press release. “I am passionate about the spirit of voluntarism, especially in advancing the sciences, so I very much look forward to serving the AAPS membership and working with the dedicated AAPS staff on the continuing success and growth of the organization.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5